Control release formulation containing a hydrophobic material as the sustained release agent
CA 2518442 A1 · Owner: Nostrum Pharmaceuticals, Inc. · Inventors: Mulye, Nirmal
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to a sustained release pharmaceutical composition in oral dosage form consisting essentially of a pharmaceutically effective amount of a medicament and a hydrophobic material in the absence of a lactose or hydrophobic carbohydrate polymer said medicament being present , in an amount greater than about 25% of the pharmaceutical composition and having a water solubility greater than about 1 gram per 10 mL of water at 25~C, said hydrophobic material having a melting point ranging from at least about 40~C to about 100~C at 1 atm pressure and being present in an amount , ranging from about 3% to about 20% by weight of the pharmaceutical composition and in …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 4, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 4, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 4, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.